J&J expected to report lower earnings

Health-care conglomerate Johnson & Johnson is expected to report moderately lower second-quarter earnings Tuesday, due in part to the recent loss of market exclusivity for the health-care conglomerate's popular Topamax drug as well as recession-weakened sales of consumer products.